Skip to main content
Caplight Logo









Enedra Therapeutics

Enedra Therapeutics

Private
LondonHealthcare & Life Scienceshttps://enedratx.com/

Last Round

VC Round

May 6, 2025

Company Overview

Enedra Therapeutics is a biotechnology company developing next-generation precision therapies for advanced, genetically heterogeneous cancers. The company leverages its proprietary AI-driven CASPAROV platform to discover novel drug targets and patient-specific biomarkers.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

AI drug discoverydrug target discoveryprecision oncologytechbioAI biotechdrug discovery platformcomputational biologybioinformaticsin silico drug discoverygenomics platformtumor heterogeneitytherapeutic resistancepreclinical biotechfirst-in-class drugsbiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enedra Therapeutics Comparables

Compare Enedra Therapeutics with similar companies based on industry and business-model similarity.

Enedra Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mosaic Therapeutics
86%
Tailor Bio
84%
Evariste
80%

Enedra Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 6, 2025

Enedra Therapeutics Investors

Notable investors and investment history

Enedra Therapeutics investors
InvestorRounds
Deep Science VenturesSeed, VC Round
o2h venturesVC Round
Centre for Drug Design and DiscoveryVC Round
Cancer Research HorizonsSeed, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2025

    Raised VC Round led by o2h ventures and Centre for Drug Design and Discovery.

Enedra Therapeutics Filings

Explore SEC and related filing metadata, where available.

Enedra Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Enedra Therapeutics's valuation, stock price, and market status.

Is Enedra Therapeutics a public or private company?

Enedra Therapeutics is a private company.

What is the current stock price of Enedra Therapeutics?

Enedra Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Enedra Therapeutics worth (valuation)?

Valuation information for Enedra Therapeutics is not publicly available.

Can I buy Enedra Therapeutics stock?

Enedra Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Enedra Therapeutics's last funding round?

Enedra Therapeutics's most recent funding round was VC Round on May 6, 2025.

Who are the main investors in Enedra Therapeutics?

Key investors in Enedra Therapeutics include o2h ventures, Centre for Drug Design and Discovery.

Will Enedra Therapeutics IPO soon?

No public IPO plans have been announced for Enedra Therapeutics.

How can I track Enedra Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Enedra Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Year Founded2021
Last FundingMay 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?